Working… Menu

Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02165683
Recruitment Status : Completed
First Posted : June 17, 2014
Last Update Posted : June 28, 2017
Information provided by (Responsible Party):
Lars Wagner, University of Kentucky

Brief Summary:
This is a single-arm, open-label study to assess the safety and effectiveness of a single dose of oral propranolol in reducing18F-fluorodeoxyglucose (FDG) uptake in brown adipose tissue (BAT) in pediatric oncology patients. This study is designed to better understand if taking a single dose of an oral medication called propranolol can reduce the chance of brown fat showing up on a PET scan, and therefore make the scan more accurate and easy to interpret. All humans have some degree of normal brown fat (called brown adipose tissue), and this normal tissue can sometimes light up on a PET scan. That creates problems because it may be wrongly interpreted by the radiologist as tumor, or it may hide true areas of tumor underneath it. Participants will not be randomized and will receive a single dose of oral propranolol approximately 60 minutes prior to the injection of the FDG tracer. The dose of propranolol will be 20 mg for all participants.

Condition or disease
Pediatric Cancer

Detailed Description:

In this study, participants will be assessed in the University of Kentucky DanceBlue Pediatric Hematology/Oncology clinic to confirm they are eligible for the study. This will be done at the time intravenous (iv) access is started, either through an iv placed in the arm or through a port/central line.

All females who are capable of becoming pregnant will then undergo urine pregnancy testing. If it is found that they are pregnant they will not be allowed to be in the study. Participant blood sugar will be checked. When possible, the research blood sample will be collected at a time when routine non-research labs will be collected.

Study eligible participants will then be given a single 20 mg tablet of propranolol to take by mouth and will be escorted by a member of the medical team to the PET scan trailer, where they will be checked in and assessed. Blood sugar level will again be checked by finger stick according to the standard procedure for PET scans.

Vital signs will be assessed by a clinical research nurse at least three times while the participants are at the PET scan trailer, including twice before the scan and once immediately after the scan. The nurse will also assess for any symptoms related to the propranolol. If no problems are noted, participants will be discharged from the PET scan trailer and their tudy participation will end. If any side effects arise from the medication, the pediatric oncologist will be called immediately and appropriate treatment started. The PET scan will be assessed by the radiologist to see whether there is uptake in brown fat, as well as to see if any areas of tumor are seen.

Layout table for study information
Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Investigation of Propranolol Premedication to Reduce FDG Uptake in Brown Adipose Tissue on PET Scans of Pediatric Cancer Patients
Study Start Date : July 2014
Actual Primary Completion Date : October 24, 2016
Actual Study Completion Date : October 24, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans

Primary Outcome Measures :
  1. Number of Adverse Events following Propranolol dosing [ Time Frame: 1 day ]
    The primary objective of our study will be to document the safety of using a single dose of propranolol.

Secondary Outcome Measures :
  1. Number of Reductions in FDG Uptake in BATWhen Compared to Historic Controls [ Time Frame: 2 years ]
    We will test the hypothesis that the use of propranolol given prior to the PET scan results in a statistically significant reduction in FDG uptake in BAT compared to historical controls.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 29 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
11 Male and female participants from all races and ethnic backgrouns who are receiving treatment by the University of Kentucky Medical Center, Pediatric Oncology divsion.

Inclusion Criteria:

  • Individual is between 12 years and 29 years of age
  • Individual weighs over 66 pounds
  • Individual will be undergoing a FDG-PET scan as part of staging or response assessment for malignancy. Note: the patient may be newly-diagnosed, currently receiving therapy, or have already completed therapy. The presence of identifiable tumor on the PET scan is not required.
  • Individual is able to swallow a tablet

Exclusion Criteria:

  • Prior diagnosis of asthma, OR use of an inhaler in past three years to treat or prevent bronchospasm.
  • History of cardiac arrhythmia requiring treatment
  • History of congestive heart failure
  • Current use of medications to control blood pressure or improve cardiac output
  • Diabetes Type I or II, or currently on medications to reduce blood sugar
  • Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02165683

Layout table for location information
United States, Kentucky
University of Kentucky DanceBlue Pediatric Hematology/Oncology Clinic
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
Lars Wagner
Layout table for investigator information
Principal Investigator: Lars Wagner, MD University of Kentucky, Dept of Pediatric Hematology/Oncology

Layout table for additonal information
Responsible Party: Lars Wagner, Sponsor/PI, University of Kentucky Identifier: NCT02165683     History of Changes
Other Study ID Numbers: 14-0468-F3r
First Posted: June 17, 2014    Key Record Dates
Last Update Posted: June 28, 2017
Last Verified: June 2017
Keywords provided by Lars Wagner, University of Kentucky:
PET Scan
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents